- 1 Title:
- 2 Clinical presentation and differential splicing of *SRSF2*, *U2AF1* and *SF3B1* mutations in
- 3 patients with Acute Myeloid Leukaemia
- 4 Running Head:
- 5 Characterization of SF mutations in AML
- 6 Stefanos A. Bamopoulos^{1,2}, Aarif M. N. Batcha^{3,4}, Vindi Jurinovic^{1,3}, Maja Rothenberg-
- 7 Thurley¹, Hanna Janke¹, Bianka Ksienzyk¹, Julia Philippou-Massier⁵, Alexander Graf⁵, Stefan
- 8 Krebs⁵, Helmut Blum⁵, Stephanie Schneider^{1,6}, Nikola Konstandin¹, Maria Cristina
- 9 Sauerland⁷, Dennis Görlich⁷, Wolfgang E. Berdel⁸, Bernhard J. Woermann⁹, Stefan K.
- 10 Bohlander¹⁰, Stefan Canzar¹¹, Ulrich Mansmann^{3,4,12,13}, Wolfgang Hiddemann^{1,12,13}, Jan
- 11 Braess¹⁴, Karsten Spiekermann^{1,12,13}, Klaus H. Metzeler^{1,12,13} and Tobias Herold^{1,12,15}

- 13 1 Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU
- 14 Munich, Munich, Germany
- 2 Department of Hematology and Oncology (CBF), Charité University Medicine, Berlin, Ger many
- 17 3 Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Mu-
- 18 nich, Germany
- 19 4 DIFUTURE (Data integration for Future Medicine (DiFuture, www.difuture.de), LMU Munich,
- 20 Munich, Germany
- 5 Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich,
- 22 Germany
- 23 6 Institute of Human Genetics, University Hospital, LMU Munich, Munich, Germany

- 24 7 Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany
- 25 8 Department of Medicine, Hematology and Oncology, University of Münster, Münster, Ger-
- 26 many
- 27 9 German Society of Hematology and Oncology, Berlin, Germany
- 10 Leukaemia and Blood Cancer Research Unit, Department of Molecular Medicine and Pa-
- 29 thology, University of Auckland, Auckland, New Zealand
- 30 11 Gene Center, LMU Munich, Munich, Germany
- 31 12 German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
- 32 13 German Cancer Research Center (DKFZ), Heidelberg, Germany
- 33 14 Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg,
- 34 Germany
- 35 15 Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München,
- 36 German Center for Environmental Health (HMGU), Munich, Germany

37 **Corresponding Authors:**

- 38 Stefanos A. Bamopoulos; stefanos.bamopoulos@charite.de
- 39 **and**
- 40 Tobias Herold, MD; Marchioninistr. 15; 81377 Munich; Germany; Phone: +49 89 4400-0; FAX:
- 41 +49 89 4400-74242; Email: tobias.herold@med.uni-muenchen.de

43 **Abstract**

44 Previous studies demonstrated that splicing factor mutations are recurrent events in 45 hematopoietic malignancies with both clinical and functional implications. However, their 46 aberrant splicing patterns in acute myeloid leukaemia remain largely unexplored. In this study we characterized mutations in SRSF2, U2AF1 and SF3B1, the most commonly mutated 47 splicing factors. In our clinical analysis of 2678 patients, splicing factor mutations showed 48 49 inferior relapse-free and overall survival, however, these mutations did not represent 50 independent prognostic markers. RNA-sequencing of 246 and independent validation in 177 51 patients revealed an isoform expression profile highly characteristic for each individual 52 mutation, with several isoforms showing a strong dysregulation. By establishing a custom 53 differential splice junction usage pipeline we accurately detected aberrant splicing in splicing 54 factor mutated samples. Mutated samples were characterized predominantly by decreased 55 junction usage. A large proportion of differentially used junctions were novel. Targets of 56 splicing dysregulation included several genes with a known role in leukaemia. In 57 SRSF2(P95H) mutants we further explored the possibility of a cascading effect through the 58 dysregulation of the splicing pathway. We conclude that splicing factor mutations do not 59 represent independent prognostic markers. However, they do have genome-wide 60 consequences on gene splicing leading to dysregulated isoform expression of several genes.

61 Introduction

The discovery of recurring somatic mutations within splicing factor genes in a large spectrum 62 63 of human malignancies has brought attention to the critical role of splicing and its complex 64 participation in carcinogenesis [1-3]. The spliceosome is a molecular machine assembled from small nuclear RNA (snRNA) and proteins and is responsible for intron removal (splicing) 65 in pre-messenger RNA. In acute myeloid leukaemia (AML), splicing factor mutations occur 66 67 most frequently in SRSF2, U2AF1 and SF3B1. The splicing factors encoded by these genes 68 are all involved in the recognition of the 3'-splice site during pre-mRNA processing.[4] Splicing factor (SF) mutations are especially common in haematopoietic malignancies, where they 69 70 occur early on and remain stable throughout the disease evolution of myelodysplastic 71 syndromes (MDS) [1,5–9]. SF mutations are also prevalent in acute myeloid leukaemia 72 (AML), which is often the result of myeloid dysplasia progression, with reported frequencies of 6-10%, 4-8% and 3% for SRSF2, U2AF1 and SF3B1 mutations respectively [2,4,10,11]. 73

74 SF mutations rarely co-occur within the same patient, implying the lack of a synergistic effect 75 or synthetic lethality [1,2,6]. They are typically heterozygous point mutations, frequently 76 coincide with other recurrent mutations in haematopoietic malignancies and are associated 77 with aberrant splicing in genes recurrently mutated in AML [2,4,8]. Notably, the aberrant 78 splicing patterns are distinct for each SF mutation, suggesting that SF mutations do not share 79 the same mechanism of action and should be recognized as individual alterations [4,9,12–17]. 80 The clinical characteristics and outcome of patients with SF mutations are well defined in 81 MDS [1,3,8,9]. Meanwhile, attempts at determining the role of SF mutations as independent 82 prognostic markers in AML have often been limited to specific subgroups and it remains unclear whether the inferior survival associated with SF mutations is confounded by their 83 84 association with older age or accompanying mutations [10,18]. Additionally, while evidence of

aberrant splicing due to SF mutations has emerged for many genes relevant in AML, it is yet
 uncertain whether and how these changes directly influence disease initiation or evolution.

The aim of this study was a comprehensive analysis of the prognostic implications of SF mutations in two well-characterized and intensively treated adult AML patient cohorts amounting to a total of 2678 patients. In addition, the core functional consequences of SF mutations were explored using targeted amplicon sequencing in conjunction with RNAsequencing on two large datasets.

92 **Patients and Methods**

93 **Patients**

Our primary cohort included a total of 1138 AML patients treated with intensive chemotherapy in two randomized multicenter phase 3 trials of the German AML Cooperative Group (AMLCG). Treatment regimens and inclusion criteria are described elsewhere [2]. A cohort of 1540 AML patients participating in multicenter clinical trials of the German-Austrian AML Study Group (AMLSG), was used for validation [19]. Cohort composition and filtering criteria are outlined in the supplementary.

100 Molecular Workup

All participants of the AMLCG cohort received cytogenetic analysis, as well as targeted DNAsequencing as described previously [2]. The subset of the AMLSG cohort included in this study received a corresponding molecular workup, described elsewhere [19].

104 RNA-Sequencing and data processing

105 Using the Sense mRNA Seq Library Prep Kit V2 (Lexogen; Vienna, Austria) 246 samples 106 underwent poly(A)-selected, strand-specific, paired-end sequencing on a HiSeq 1500 107 instrument (Illumina; San Diego, CA, USA). A subset of the Beat AML cohort (n=177) was 108 used for validation [20]. The same bioinformatics analysis was used for both datasets and is 109 described in the supplementary. The samples were aligned to the reference genome 110 (Ensembl GRCh37 release 87) using the STAR [21] aligner with default parameters. Splice 111 junctions from all samples were pooled, filtered and used to create a new genomic index. 112 Multi-sample 2-pass alignments to the re-generated genome index followed, using the STAR 113 recommended parameters for gene-fusion detection. Read counts of transcripts and genes 114 were measured with salmon [22]. Read counts of splice junctions were extracted from the 115 STAR output.

116

117 Differential expression analysis and differential splice junction usage (DSJU)

A minimum expression filter was applied prior to each differential analysis. Differentially expressed isoforms were identified with the limma [23] package after TMM-normalization [24] with edgeR [25] and weighting with voom [26,27]. A surrogate variable analysis step using the sva [28] package was included to reduce unwanted technical noise. DSJU was quantified similarly using the diffSplice function of the limma package. Both analyses are described in detail in the supplementary.

124 Nanopore cDNA sequencing and analysis

Total RNA was transcribed into cDNA using the TeloPrime Full-Length cDNA Amplification Kit (Lexogen) which is highly selective for polyadenylated full-length RNA molecules with 5'-cap structures. Two barcoded samples for multiplexed analysis were sequenced on the Oxford Nanopore Technologies MinION platform. Alternative isoform analysis was performed with FLAIR [29].

130 Statistics

131 Statistical analysis was performed using the R-3.4.1 [30] software package. Correlations 132 between variables were performed using the Mann-Whitney U test and the Pearson's chi-133 squared test. In case of multiple testing, p-value adjustment was performed as described in 134 the supplementary. Survival analysis was performed and visualized using the Kaplan-Meier 135 method and the log-rank test was utilized to capture differences in relapse free survival (RFS) 136 and overall survival (OS). Patients receiving an allogeneic stem cell transplant were censored 137 at the day of the transplant, for both RFS and OS. Additionally, Cox regressions were performed for all available clinical parameters and recurrent aberrations. Cox multiple 138 139 regression models were then built separately for RFS and OS, using all variables with an

140 unadjusted p-value < 0.1 in the single Cox regression models.

141 **Results**

142 Clinical features of AML patients with SF mutations

We characterized SF mutations in two independent patient cohorts (the AMLCG and AMLSG 143 144 cohorts). Our primary cohort (AMLCG) consisted of 1119 AML patients (Figure S1), 236 (21.1%) of which presented with SF mutations. The three most commonly affected SF genes. 145 146 SRSF2, U2AF1 and SF3B1 were mutated in 12.1% (n=136), 3.4% (n=38) and 4.1% (n=46) of 147 the patients (Figure 1A). In agreement with previous findings [19], SF mutations were in their 148 majority mutually exclusive, heterozygous hotspot mutations (Figure 1B). The four most 149 common point mutations were SRSF2(P95H) (n=69), SRSF2(P95L) (n=27), U2AF1(S34F) (n=18), and SF3B1(K700E) (n=18) mutations (Figure 1C-E). The clinical characteristics of 150 151 patients harboring SF mutations are summarized in Tables 1 and S1 (AMLSG cohort), along 152 with a statistical assessment between cohorts (Table S2). We observed a high overall degree of similarity regarding clinical features of SF mutated patients between the AMLCG and 153 AMLSG cohorts, despite their large median age difference. Mutations in SRSF2, U2AF1 and 154 155 SF3B1 occurred more frequently in secondary AML (44.7% compared to 18.2% in de novo 156 AML) and were all associated with older age. As reported previously [1], SRSF2 and U2AF1 157 mutated patients were predominantly male (76.7% and 76.3%, respectively). Furthermore, 158 patients harboring SRSF2 mutations presented with a lower white blood cell count (WBC; median 13.3 10⁹/L vs. 22.4 10⁹/L) while U2AF1 mutated patients presented with a reduced 159 160 blast percentage in their bone marrow when compared to SF wildtype patients (median 60%) 161 vs 80%).

162 Associations of SF mutations and other recurrent alterations in AML

In a second step, we investigated associations between SF mutations and recurrent
 cytogenetic abnormalities and gene mutations in AML (Figure 2). Notably, SF mutations were

not found in inv(16)/t(16;16) patients (n=124), with the exception of one inv(16)/t(16;16) patient harboring a U2AF1(R35Q) mutation. The same held true for t(8;21) patients (n=98), where only one patient had a rare deletion in *SRSF2*. Additionally, all patients in the AMLCG cohort presenting with an isolated trisomy 13 (n=9) also harbored an *SRSF2* mutation (p<0.001), as described previously [31].

170 Mutations in all SF genes correlated positively with mutations in BCOR and RUNX1 and 171 negatively with mutations in NPM1. Expectedly, SRSF2(P95H) and SRSF2(P95L) mutations 172 shared a similar pattern of co-expression including significant pairwise associations with 173 mutations in ASXL1, IDH2, RUNX1 (both p<0.001) and STAG2 (p<0.001 and p=0.002, 174 respectively). However, apart from IDH2 mutations where co-occurrence was comparable 175 (OR: 3.4 vs 5.1), mutations in ASXL1, RUNX1 and STAG2 coincided more frequently with 176 SRSF2(P95H) mutations. Despite this, SRSF2(P95L) mutations showed a slightly increased 177 co-occurrence with other recurrent AML mutations (median 5 vs 4 mutations, p=0.046).

178 **Prognostic relevance of SF mutations for relapse-free survival and overall survival**

The prognostic impact of *SRSF2*, *U2AF1* and *SF3B1* mutations was initially assessed using Kaplan-Meier graphs and log-rank testing. All SF mutations presented with both inferior relapse-free survival (RFS) and overall survival (OS) compared to SF wildtype patients (Figures S3.1A-C and S3.2). The effect was most pronounced in *U2AF1* mutated patients with an one-year survival rate of only 29.1%, followed by *SF3B1* (40.6%) and *SRSF2* mutated patients (49.2%). Different point mutations inside the same SF gene did not differ significantly in their effect on OS.

To confirm the observed prognostic impact of SF mutations we performed single Cox regressions on all available clinical and genetic parameters. In agreement with the Kaplan-Meier estimates, patients harboring *SRSF2*(P95H), *SRSF2*(P95L), *U2AF1*(S34F) and

189 SF3B1(K700E) mutations had significantly reduced RFS and OS (Figures S3.1D and S4.1). 190 To test whether any SF mutation was an independent prognostic marker, multiple Cox 191 regression models (Figure 3) were built by integrating all parameters significantly associated 192 (p < 0.1) with RFS and OS in the single Cox regression models. Along with several known 193 predictors, only U2AF1(S34F) mutations presented with prognostic relevance for both RFS 194 (Hazard Ratio=2.81, p=0.012) and OS (HR=1.90, p=0.034) in the AMLCG cohort, but not in 195 the AMLSG cohort. However, when aggregating mutations at the gene level, mutations in 196 SRSF2 and SF3B1 presented with prognostic relevance for RFS in the AMLSG cohort 197 (HR=1.77, p=0.008; HR=2.15, p=0.014; respectively), while not reaching significance in the 198 AMLCG cohort (Table S4.2). When looking only at de novo AML patients, the prognostic 199 impact of U2AF1(S34F) mutations diminished, yet the prognostic impact observed for SRSF2 200 and SF3B1 remained significant in the AMLSG cohort (HR=1.84, p=0.009; HR=2.43, p=0.015;

respectively) (Tables S4.1-S4.2).

202 Differential isoform expression in SF mutated patients

We next assessed the impact of SF mutations on mRNA expression. To this end, wholetranscriptome RNA-sequencing was performed on 246 AML patients, 29 of which harbored a mutation in the SF genes of interest, while 199 SF wildtype patients were used as a control (Figure S2). The remaining patients either presented with a different SF mutation (n=17) or exhibited more than one SF mutation (n=1) and were excluded. In addition, a subset of the Beat AML cohort (n=177) with matched DNA- and RNA-sequencing data was used for validation [20].

After low-coverage filtering we performed a differential isoform expression analysis for ~90 000 isoforms. Differential expression was restricted to a small fraction of all expressed isoforms (<0.5%; Figure 4A and Table S6.1). Little overlap of differentially expressed (DE)

213 isoforms was found when different SF mutation groups were compared to the control, 214 consistent with previous observations [32]. However, 10 isoforms were reported as DE in both 215 SRSF2(P95H) and SRSF2(P95L) mutated samples, all with the same fold-change direction 216 (Figure 4B). Out of those, the isoforms in GTF2I, H1F0, INHBC, LAMC1 and one of the 217 isoforms of METTL22 (ENST00000562151) were also significant in the validation cohort for 218 both SRSF2(P95H) and SRSF2(P95L). Additionally, the isoform of H1F0 was also reported as 219 DE for U2AF1(S34F) mutants in both cohorts. For SRSF2(P95H) mutants 107 of all DE 220 isoforms also reached significance in the validation cohort (40.1%), while for the other SF 221 mutation subgroups validation rates ranged from 15.1 to 27.3% increasing with larger mutant 222 sample sizes. Notably, mutated and wildtype samples showed large differences in the 223 expression levels of several isoforms (Figure 4C and Figure S5). The top two overexpressed 224 isoforms in SRSF2(P95H) both corresponded to INTS3, which was recently reported as 225 dysregulated in SRSF2(P95H) mutants co-expressing IDH2 mutations [33]. Several DE 226 isoforms identified in SF mutated patients correspond to cancer-related genes, many of which 227 have a known role in AML. Specifically, genes with DE isoforms included, but were not limited to BRD4 [34], EWSR1 [35] and YBX1 [36] in SRSF2(P95H) mutated samples, CUX1 [37], 228 229 DEK [15,38] and EZH1 [39] in U2AF1(S34F) mutated samples, as well as PTK2 [40] in 230 SF3B1(K700E) mutated patients (Tables S7.1-S7.2).

Hierarchical clustering using DE isoforms was performed for all samples to assess the expression homogeneity of SF mutations. A tight clustering of samples harboring identical SF point mutations was observed, indicating an isoform expression profile highly characteristic for each individual SF mutation (Figures S6.1-S6.3). When using DE isoforms resulting from the comparison of all *SRSF2* mutated samples against SF wildtype samples, the samples did not cluster as well. This stands in agreement with the limited overlap of differentially

expressed isoforms found between the two *SRSF2* point mutations examined and suggests at
least some heterogeneity among them. The same also held true for *U2AF1* mutated samples,
however all *SF3B1* mutated samples still clustered together when compared as a single
group to the control.

241 **Differential splicing in SF mutants**

242 Previous studies have reported differential splicing as causal for isoform dysregulation in SF 243 mutants [41,42]. To detect aberrant splicing in our dataset, we quantified the usage of all 244 unique splice junctions by pooling information from all samples (Figure S7). After filtering out junctions with low expression, 235 730 junctions were assigned to genes. Only junctions 245 246 within an annotated gene were considered, leading to the exclusion of 11 617 (4.9%) 247 junctions. Junctions present in genes with low-expression or genes with a single junction were 248 excluded, leaving 221 249 unique junctions (19.3% novel) across 15 526 genes (Table S6.1). 249 Applying the same workflow to the Beat AML cohort yielded 194 158 junctions (8.3% novel). 250 Notably, of the 172 518 junctions shared across both datasets, 10 029 (5.8%) were novel. The 251 novel junctions passing our filtering criteria were supported by a high amount of reads and 252 samples with a distribution comparable to that of annotated junctions (Figure 5A). Neither the 253 number of novel junctions nor the number of reads supporting them correlated with the 254 presence of SF mutations, suggesting that novel splicing events are not increased in SF 255 mutants.

In consideration of the high proportion of novel junctions in both datasets, we employed a customized pipeline that can quantify the differential splice junction usage (DSJU) of each individual junction, by harnessing usage information from all junctions inside one gene. Of the several hundred junctions reported as differentially used in our primary cohort (p<0.05, log_2 (fold change) > 1), 20.2-45.9% constituted novel junctions (Tables S7.1-S7.3 and Tables

261 S9.1-S9.2) and were classified according to their relationship with known acceptor and donor 262 sites as described previously (Figure 5B) [15]. Unsurprisingly, validation rates increased with 263 larger mutant sample sizes, ranging from 9.3% (SF3B1(K700E); n = 3) to 74.0% (all SRSF2 264 mutants; n = 26). Furthermore, validation rates were higher for novel junctions (mean 39.3%) vs. 21.5% known junctions), likely due to the stricter initial filtering criteria applied. By 265 performing nanopore sequencing of one SRSF2(P95H) mutant and one SF wildtype sample 266 267 we were able to confirm the usage of several novel junctions and detect resulting novel 268 isoforms as exemplified for IDH3G in Figure 6A-D. A tendency towards decreased junction 269 usage was observed for all SF point mutations and was most evident in SF3B1(K700E) 270 mutants (1 423/1 927; 73.9% of differentially used junctions). The total number of splicing 271 events, however, was not reduced in SF mutants (mean 9,275,359 events vs. 9 192 697 in 272 wildtype patients), suggesting that decreased splicing is limited to selected junctions rather 273 than being a global effect.

274 We systematically compared the genes with at least one DE isoform and those reported as 275 differentially spliced in all SF mutation subgroups (Tables S9.3-S9.4). For SRSF2 mutants, 276 genes significant in both analyses included EWSR1, H1F0, INTS3 and YBX1. In general, out 277 of the genes examined in both analyses only 9.8-23.3% (depending on the SF mutation) of 278 genes reported as having a DE isoform were also reported as being differentially spliced. 279 Conversely, 3.3-28.5% of differentially spliced genes were also reported as having a DE 280 isoform. These findings suggest that differential gene splicing does not always lead to altered 281 isoform expression while at the same time differential isoform expression cannot always be 282 attributed to an explicit splicing alteration. Considering the complementary nature of the analyses, we performed gene ontology (GO) analysis by combining the genes with evidence 283 284 of differential isoform usage or differential splicing (Tables S10.1-S10.7). Interestingly, GO

terms enriched for both *SRSF2* mutants included "mRNA splicing, via spliceosome" (p<0.001 and p=0.046, respectively) and "mRNA splice site selection" (p=0.022 and p=0.019, respectively) (Figure 5C).

288 In an additional step, the splice junction counts reported by Okeyo-Owuor et al. were used to detect DSJU between CD34+ cells with U2AF1(S34) mutations (n=3) and SF wildtype (n=3) 289 290 via the same pipeline applied to the AMLCG and Beat AML cohorts. While no identical 291 junctions were differentially used in all three datasets, 16 genes were reported as differentially 292 spliced in all, including leukemia or cancer-associated genes (ABI1, DEK, HP1BP3, MCM3 293 and SET), as well as HNRNPK (a major pre-mRNA binding protein), thereby further refining 294 our list of genes with strong evidence of differential splicing between U2AF1(S34F) mutants 295 and SF wildtype samples (Table S11).

296 The effect of SF mutations on the splicing pathway

297 It is well established that SF mutations dysregulate splicing by changing RNA binding affinities 298 or altering 3' splice site recognition of the corresponding splicing factors. However, SRSF2 299 also plays a splicing-independent role in transcriptional pausing by translocating the positive 300 transcription elongation factor complex (P-TEFb) from the 7SK complex to RNA polymerase II 301 [43]. A recent study reported that mutant SRSF2(P95H) enhances R-loop formation due to 302 impaired transcriptional pause release, thus providing evidence that altered splicing does not 303 account for the entirety of the SRSF2(P95H) mutant phenotype [32]. In another study no 304 difference was found in the total mRNA of 12 Serine/arginine rich splicing factors and 14 out 305 of 16 major heterogeneous nuclear ribonucleoprotein (hnRNP) splicing factors between 306 SRSF2(P95H) mutant and WT CRISPR clones [44].

We cross-referenced our differential expression and differential splicing analysis results with a list of all genes involved in splicing (GO:0000398; mRNA splicing, via spliceosome). Of the

309 347 splicing-related genes (317 of which were expressed in our dataset) 101 were 310 dysregulated in at least one SF mutant group. On average 30.5 (range 6-52) splicing-related 311 genes were dysregulated per SF point mutation. Of note, both SRSF2 point mutations 312 associated with differential splicing of HNRNPA1 and HNRNPUL1, as well as PCF11 and 313 TRA2A. A query of the STRING database suggests protein-protein interactions between 314 SRSF2 and the proteins of the above genes, which are also interconnected (Figure 6E). 315 Interestingly, one of the differential splicing events reported in both SRSF2 mutants involves 316 the under-usage of the same novel splice junction in TRA2A (Figure 6F). TRA2A has 317 previously been shown to be differentially spliced in mouse embryo fibroblasts upon SRSF2 318 knockout [45]. Furthermore, it has been shown that both HNRNPA1 and SRSF2 interact with 319 the loop 3 region of 7SK RNA and by favoring the dissociation of SRSF2, HNRNPA1 may 320 lead to the release of active P-TEFb [46]. Taken together, our results indicate a strong 321 dysregulation of the splicing pathway in SF mutants including several genes whose gene 322 products closely interact with SRSF2.

323

325 Discussion

The clinical relevance of SF mutations and their aberrant splicing patterns have been explored in myelodysplasia, while comparable data for AML is lacking. In this study we examined two AML patient cohorts, encompassing a total of 2678 patients from randomized prospective trials, to characterize SF mutations clinically. This analysis was complemented by RNA-sequencing analysis of two large datasets to reveal targets of aberrant splicing in AML.

We show that SF mutations are frequent alterations in AML, identified in 21.4% of our primary patient cohort, especially in elderly patients and in secondary AML. SF mutations are associated with other recurrent mutations in AML, such as *BCOR* and *RUNX1* mutations, however *SRSF2*(P95L) mutations co-occur less often with those mutations when compared to *SRSF2*(P95H) mutations, albeit showing a slightly increased mutational load. This suggests a more diverse co-expression profile of *SRSF2*(P95L).

337 Previous studies have demonstrated the predictive value of SF mutations in clonal 338 haematopoiesis of indeterminate potential (CHIP) [47], MDS [6,8,48-50] and AML 339 [10,18,19,51]. However, survival analyses in AML were, in their majority, hampered by small 340 sample sizes and limited availability of further risk factors. Therefore, we examined whether 341 SF mutations impact survival while accounting for recently proposed risk parameters included 342 in the ELN 2017 classification [52]. In our analysis, SRSF2 and SF3B1 mutations were no 343 independent prognostic markers for OS in AML. U2AF1(S34F) mutations displayed poor OS 344 in the AMLCG cohort, which we were unable to validate in the AMLSG cohort. The 345 discrepancy in survival of SF mutated patients between the two cohorts lied most likely in the 346 large age difference of the participants (median age difference of 8 years), which also led to a higher percentage of patients receiving allogeneic transplants in the AMLSG cohort (56.5% 347 348 vs. 30.6% in the AMLCG cohort). In summary, SF mutations are early evolutionary events and

define prognosis and transformation risk in CHIP and MDS patients, yet there is no clear
 independent prognostic value of SF mutations in AML.

351 Two large RNA-sequencing studies have been performed previously, to detect aberrantly 352 spliced genes in SF mutants, both of which focused on MDS patients [41,42]. In this study we described a distinct differential isoform expression profile for each SF point mutation. 353 354 Furthermore, we evaluated differential splicing for the four most common SF point mutations 355 via a customized pipeline to determine differential usage of both known and novel splice 356 junctions. Our pipeline enables the differential quantification of individual splice junctions 357 without restricting the analysis to annotated alternative splicing events. We argue that the 358 strength of our analysis lies in the accurate detection of single dysregulated junctions 359 (especially in cases where splice sites are shared by multiple junctions) in an annotation-360 independent manner achieving validation rates up to 74.0% in our largest mutant sample 361 group (SRSF2, n=19). Limitations of the analysis include the restriction to junctions with both 362 splice sites within the same gene (a restriction shared by most differential splicing algorithms) 363 and genes with at least two junctions. However, the reduced requirements of our analysis 364 could prove valuable in the study of differential splicing in organisms with lacking annotation.

365 All SF point mutations shared a tendency towards decreased splice junction usage, which did 366 not affect the global number of splicing events in SF mutants. Surprisingly, we observed a 367 limited overlap between genes with differentially expressed isoforms and differentially spliced 368 genes. In addition, a recent study by Liang et al. reported that the majority of differential 369 binding events in SRSF2(P95H) mutants do not translate to alternative splicing [53]. Taken 370 together, these findings indicate a "selection" or possibly a compensation of deregulatory events from differential binding through differential splicing to finally differential isoform 371 372 expression. Furthermore, the enrichment of aberrant splicing in splicing-related genes opens

373 the possibility of a cascading effect on transcription via the differential alternative splicing of 374 transcriptional components. A congruent hypothesis was stated by Liang et al., where an 375 enrichment of SRSF2(P95H) targets in RNA processing and splicing was shown, further 376 supporting the notion of an indirect effect of mutant SRSF2 facilitated through additional 377 splicing components. Further investigations may provide a mechanistic link between the 378 differential splicing of selected genes and the impairment of transcription and specifically 379 transcriptional pausing observed in SF mutant cells, which contributes to the MDS phenotype 380 [32].

To the best of our knowledge our study represents the most comprehensive analysis of SF 381 382 mutations in AML to date, both in terms of clinical and functional characterization. This 383 enabled us to study SRSF2(P95H) and SRSF2(P95L) separately, thereby not only outlining 384 their differences but also identifying common and likely core targets of differential splicing in 385 SRSF2 mutants. We conclude that SF mutated patients represent a distinct subgroup of AML 386 patients with poor prognosis that is not attributable solely to the presence of SF mutations. SF 387 mutations induce aberrant splicing throughout the genome including the dysregulation of 388 several genes associated with AML pathogenesis, as well as a number of genes with 389 immediate, functional implications on splicing and transcription. Further studies are required 390 to identify which splicing events are critical in leukaemogenesis and whether they are 391 accessible to new treatments options, such as splicing inhibitors [54] and immunotherapeutic 392 approaches.

393 Acknowledgments

394 The authors thank all participants and recruiting centers of the AMLCG, BEAT and AMLSG

395 trials.

396

397 Funding

- 398 This work is supported by a grant of the Wilhelm-Sander-Stiftung (no. 2013.086.2) and the
- 399 Physician Scientists Grant (G-509200-004) from the Helmholtz Zentrum München to T.H. and
- 400 the German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung,
- 401 Heidelberg, Germany). K.H.M., K.S. and T.H. are supported by a grant from Deutsche
- 402 Forschungsgemeinschaft (DFG SFB 1243, TP A06 and TP A07). S.K.B. is supported by
- 403 Leukaemia & Blood Cancer New Zealand and the family of Marijanna Kumerich. A.M.N.B. is

404 supported by the BMBF grant 01ZZ1804B (DIFUTURE).

405

406 **Author Contributions**

407 S.A.B., A.M.N.B. and T.H. conceived and designed the analysis. S.A.B., A.M.N.B., V.J., M.R.-

408 T., H.J., A.G., S.C., N.K., K.S., K.H.M. and T.H. provided and analyzed data. A.M.N.B., V.J.

409 and U.M. provided bioinformatics support. J.P.-M., S.K. and H.B. managed the Genome

- 410 Analyzer IIx platform and the RNA-sequencing of the AMLCG samples. M.R.-T., H.J., B.K.,
- 411 S.S., N.K., S.K.B., K.H.M. and K.S. characterized patient samples; M.C.S., D.G., W.B., B.W.,
- 412 J.B. and W.H. coordinated the AMLCG clinical trials. S.A.B. and T.H. wrote the manuscript. All
- 413 authors approved the final manuscript.
- 414

415 Additional Information

416 The authors declare no conflicts of interest.

417 References

418	1.	Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al.
419		Clinical and biological implications of driver mutations in myelodysplastic syndromes.
420		2013;122(22):3616–27.
421	2.	Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D, et al.
422		Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
423		2016;128(5):686–98.
424	3.	Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Kar SA, Jerez A, et al.
425		Mutations in the spliceosome machinery, a novel and ubiquitous pathway in
426		leukemogenesis. 2012;119(14):3203–10.
427	4.	Larsson CA, Cote G, Quintás-Cardama A. The changing mutational landscape of acute
428		myeloid leukemia and myelodysplastic syndrome. 2013;11(8):815–27.
429	5.	Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent
430		pathway mutations of splicing machinery in myelodysplasia. 2011;478(7367):64–9.
431	6.	Thol F, Kade S, Schlarmann C, Löffeld P, Morgan M, Krauter J, et al. Frequency and
432		prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with
433		myelodysplastic syndromes. 2012;119(15):3578-84.
434	7.	Dolatshad H, Pellagatti A, Fernandez-Mercado M, Yip BH, Malcovati L, Attwood M, et
435		al. Disruption of SF3B1 results in deregulated expression and splicing of key genes and
436		pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
437		2015;29(5):1092–103.

Wu S, Kuo Y, Hou H, Li L, Tseng M, Huang C, et al. The clinical implication of SRSF2
mutation in patients with myelodysplastic syndrome and its stability during disease

440 evolution. 2014;120(15):3106–12.

- Graubert TA, Shen D, Ding L, Okeyo-owuor T, Cara L, Shao J, et al. Recurrent
 Mutations in the U2AF1 Splicing Factor In Myelodysplastic Syndromes. 2012;44(1):53–
 7.
- Hou H-A, Liu C-Y, Kuo Y-Y, Chou W-C, Tsai C-H, Lin C-C, et al. Splicing factor
 mutations predict poor prognosis in patients with de novo acute myeloid leukemia.
 2016;7(8).
- 11. Cho Y-U, Jang S, Seo E-J, Park C-J, Chi H-S, Kim D-Y, et al. Preferential occurrence of
 spliceosome mutations in acute myeloid leukemia with a preceding myelodysplastic
 syndrome and/or myelodysplasia morphology. 2014;8194(November):1–25.
- 450 12. Moon H, Cho S, Loh TJ, Jang HN, Liu Y, Choi N, et al. SRSF2 directly inhibits intron
 451 splicing to suppresses cassette exon inclusion. 2017;50(8):423–8.
- 452 13. Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SCW, Ramakrishnan A, et al. SRSF2
 453 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon
- 454 Recognition. 2015;27(5):617–30.
- 455 14. Alsafadi S, Houy A, Battistella A, Popova T, Wassef M, Henry E, et al. Cancer-

456 associated SF3B1 mutations affect alternative splicing by promoting alternative
457 branchpoint usage. 2016;7:10615.

- 458 15. Okeyo-Owuor T, White BS, Chatrikhi R, Mohan DR, Kim S, Griffith M, et al. U2AF1
 459 mutations alter sequence specificity of pre-mRNA binding and splicing. 2015;29(4):909–
 460 17.
- 16. Przychodzen B, Jerez A, Guinta K, Sekeres MA, Padgett R, Maciejewski JP, et al.

- 462 Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms.
- 463 2013;122(6):999–1006.
- 464 17. Shirai CL, Ley JN, White BS, Kim S, Tibbitts J, Shao J, et al. Mutant U2AF1 Expression
 465 Alters Hematopoiesis and Pre-mRNA Splicing In Vivo. 2015;27(5):631–43.
- 466 18. Yang J, Yao D, Ma J, Yang L, Guo H, Wen X, et al. The prognostic implication of SRSF2
 467 mutations in Chinese patients with acute myeloid leukemia. 2016;37(8):10107–14.
- 468 19. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al.
- 469 Genomic Classification and Prognosis in Acute Myeloid Leukemia. 2016;374(23):2209–
- 470 21.
- 471 20. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional
 472 genomic landscape of acute myeloid leukaemia. 2018;562(7728):526–31.
- 473 21. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast
 474 universal RNA-seq aligner. 2013;29(1):15–21.
- 475 22. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias476 aware quantification of transcript expression. 2017;14(4):417–9.
- Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential
 expression analyses for RNA-sequencing and microarray studies. 2015;43(7):e47–e47.
- 479 24. Robinson MD, Oshlack A. A scaling normalization method for differential expression
 480 analysis of RNA-seq data. 2010;11(3):R25.
- 481 25. Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor package for differential
 482 expression analysis of digital gene expression data. 2009;26(1):139–40.
- 483 26. Liu R, Holik AZ, Su S, Jansz N, Chen K, Leong HS an, et al. Why weight? Modelling

- 484 sample and observational level variability improves power in RNA-seq analyses.
- 485 2015;43(15):e97.
- 486 27. Law CW, Chen Y, Shi W, Smyth GK. voom: precision weights unlock linear model
 487 analysis tools for RNA-seq read counts. 2014;15(2):R29.
- 488 28. Leek JT. Svaseq: Removing batch effects and other unwanted noise from sequencing
 489 data. 2014;42(21):e161.
- 29. Tang AD, Soulette CM, Baren MJ van, Hart K, Hrabeta-Robinson E, Wu CJ, et al. Full-

491 length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia

- 492 reveals downregulation of retained introns. 2018;410183.
- 493 30. R Core Team. R: A Language and Environment for Statistical Computing [Internet].
- 494 Vienna, Austria: R Foundation for Statistical Computing;
- 495 31. Herold T, Metzeler KH, Vosberg S, Hartmann L, Ollig C, Olzel FS, et al. Isolated trisomy
- 496 13 defines a homogeneous AML subgroup with high frequency of mutations in

497 spliceosome genes and poor prognosis. 2014;124(8):1304–11.

32. Chen L, Chen J-Y, Huang Y-J, Gu Y, Qiu J, Qian H, et al. The Augmented R-Loop Is a
Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing
Factor Mutations. 2018;69(3):412-425.e6.

33. Yoshimi A, Lin K-T, Wiseman DH, Rahman MA, Pastore A, Wang B, et al. Coordinated
 alterations in RNA splicing and epigenetic regulation drive leukaemogenesis.

- 503 2019;574(7777):273–7.
- 34. Roe J-S, Vakoc CR. The Essential Transcriptional Function of BRD4 in Acute Myeloid
 Leukemia. 2016;81:61–6.

- 506 35. Endo A, Tomizawa D, Aoki Y, Morio T, Mizutani S, Takagi M. EWSR1/ELF5 induces
- 507 acute myeloid leukemia by inhibiting p53/p21 pathway. 2016;107(12):1745–54.
- 508 36. Perner F, Jayavelu AK, Schnoeder TM, Mashamba N, Mohr J, Hartmann M, et al. The
- 509 Cold-Shock Protein Ybx1 Is Required for Development and Maintenance of Acute
- 510 Myeloid Leukemia (AML) in Vitro and In Vivo. 2017;130(Suppl 1).
- 511 37. McNerney ME, Brown CD, Wang X, Bartom ET, Karmakar S, Bandlamudi C, et al.
- 512 CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently
- 513 inactivated in acute myeloid leukemia. 2013;121(6):975–83.
- 514 38. McGarvey T, Rosonina E, McCracken S, Li Q, Arnaout R, Mientjes E, et al. The acute
- 515 myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with 516 exon-product complexes. 2000;150(2):309–20.
- 517 39. Fujita S, Honma D, Adachi N, Araki K, Takamatsu E, Katsumoto T, et al. Dual inhibition
- 518 of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
- 519 2018;32(4):855–64.
- 520 40. Pallarès V, Hoyos M, Chillón MC, Barragán E, Prieto Conde MI, Llop M, et al. Focal
- Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute
 Myeloid Leukemia. 2018;10(11).
- 523 41. Shiozawa Y, Malcovati L, Gallì A, Sato-Otsubo A, Kataoka K, Sato Y, et al. Aberrant
 524 splicing and defective mRNA production induced by somatic spliceosome mutations in
 525 myelodysplasia. 2018;9(1):3649.
- 526 42. Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, et al. Impact of
- 527 spliceosome mutations on RNA splicing in myelodysplasia: Dysregulated
- 528 genes/pathways and clinical associations. 2018;132(12):1225–40.

- 529 43. Ji X, Zhou Y, Pandit S, Huang J, Li H, Lin CY, et al. SR Proteins Collaborate with 7SK
- and Promoter-Associated Nascent RNA to Release Paused Polymerase.
- 531 **2013;153(4):855–68**.
- 532 44. Zhang J, Lieu YK, Ali AM, Penson A, Reggio KS, Rabadan R, et al. Disease-associated
 533 mutation in SRSF2 misregulates splicing by altering RNA-binding affinities.
- 534 **2015;112(34):E4726–34**.
- 535 45. Skrdlant L, Stark JM, Lin R-J. Myelodysplasia-associated mutations in serine/arginine-536 rich splicing factor SRSF2 lead to alternative splicing of CDC25C. 2016;17(1):18.
- 537 46. Lemieux B, Blanchette M, Monette A, Mouland AJ, Wellinger RJ, Chabot B. A Function
- 538 for the hnRNP A1/A2 Proteins in Transcription Elongation. Caputi M, editor.
- 539 2015;10(5):e0126654.
- Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, et al.
 Prediction of acute myeloid leukaemia risk in healthy individuals. 2018;559(7714):400–
- 542 **4**.
- 543 48. Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, et
- al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and
- 545 myelodysplastic/myeloproliferative neoplasms. 2011;118(24):6239–46.
- 546 49. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al.
- 547 Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. 2011;365(15):1384–
 548 95.
- 549 50. Wu L, Song L, Xu L, Chang C, Xu F, Wu D, et al. Genetic landscape of recurrent
- 550 ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with
- 551 myelodysplastic syndromes. 2016;37(4):4633–40.

552	51.	Zhang S-J, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, et al. Genetic
553		analysis of patients with leukemic transformation of myeloproliferative neoplasms
554		shows recurrent SRSF2 mutations that are associated with adverse outcome.
555		2012;119(19):4480–5.
556	52.	Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al.
557		Diagnosis and management of AML in adults: 2017 ELN recommendations from an
558		international expert panel [Internet]. Vol. 129, Blood. 2017 [cited 2019 Feb 14]. p. 424-
559		47.
560	53.	Liang Y, Tebaldi T, Rejeski K, Joshi P, Stefani G, Taylor A, et al. SRSF2 mutations drive
561		oncogenesis by activating a global program of aberrant alternative splicing in
562		hematopoietic cells. 2018;
563	54.	Lee SCW, Abdel-Wahab O. Therapeutic targeting of splicing in cancer [Internet]. Vol.
564		22, Nature Medicine. NIH Public Access; 2016 [cited 2019 Jan 31]. p. 976–86.
565		

Table 1: Clinical characteristics of SF mutations in the AMLCG cohort.

Variables	SF wildtype	SRSF2	Р	U2AF1	Р	SF3B1	Р
No. of patients	903	133	-	38	-	45	-
Age, years, median (range)	55 (18-86)	65 (25-80)	<0.001	64 (23-74)	0.007	65 (31-78)	0.001
Female sex, no. (%)	490 (54.3)	31 (23.3)	<0.001	9 (23.7)	0.003	19 (42.2)	0.387
Hemoglobin, g/dL, median (range)	9 (3.5-16)	8.9 (3.8-14.7)	0.466	9.2 (6-13.6)	1.000	8.9 (6.8-13.4)	1.000
WBC count, 10^9/L, median (range)	22.4 (0.1-798.2)	13.3 (0.5-406)	0.008	7 (0.7-666)	0.079	22.4 (0.9- 269.5)	1.000
Platelets, 10^9/L, median (range)	55 (0-1760)	49.5 (0-643)	0.736	47 (11-132)	0.466	67 (5-585)	0.744
LDH, U/L, median (range)	448 (76-19624)	362 (150- 14332)	0.118	346 (128- 3085)	0.313	472 (142- 7434)	0.950
BM Blasts, %, median (range)	80 (6-100)	76 (15-100)	0.455	60 (10-95)	0.002	70 (13-95)	0.206
Performance Status (ECOG) > 1, no. (%)	157 (25.9)	18 (26.1)	1.000	8 (27.6)	1.000	4 (16)	0.941
primary AML, no. (%)	786 (87)	100 (75.2)	0.016	24 (63.2)	0.003	29 (64.4)	0.002
secondary AML, no (%)	69 (7.6)	30 (22.6)	<0.001	13 (34.2)	<0.001	11 (24.4)	0.021
therapy-related AML, no (%)	48 (5.3)	3 (2.3)	0.507	1 (2.6)	1.000	5 (11.1)	0.380
Allogeneic transplant, no. (%)	296 (32.8)	27 (20.3)	0.022	7 (18.4)	0.273	12 (26.7)	0.797
Complete Remission, no. (%)	641 (71)	71 (53.4)	<0.001	18 (47.4)	0.015	19 (42.2)	0.001
Relapse, no (%)	366 (63.5)	46 (82.1)	0.034	11 (78.6)	0.713	14 (87.5)	0.266
Deceased, no (%)	575 (63.7)	112 (84.2)	<0.001	34 (89.5)	0.010	41 (91.1)	0.002

568

567

569 WBC: white blood cells, LDH: lactate dehydrogenase, BM: bone marrow, ECOG: Eastern Co-

570 operative Oncology Group performance score

571

572

573

575 Figure Legends

Figure 1: Frequency and location of SF mutations. (A) Distribution of SF mutations in the AMLCG cohort. (B) Variant allele frequency of SF mutations in both study cohorts. (C) Mutation plots showing the protein location of all SF mutations in the genes *SRSF2*, *U2AF1*, and *SF3B1* for all patients of the AMLCG cohort. Number of patients harboring SF mutations are additionally provided for both cohorts.

Figure 2: Correlations between SF mutations and recurrent abnormalities. Correlation matrix depicting the co-occurrence of SF mutations and recurrent mutations in AML (A), as well as cytogenetic groups, as defined in the ELN 2017 classification (B). Only variables with a frequency >1% in the AMLCG cohort are shown. FLT3-ITD: *FLT3* internal tandem duplication mutation; FLT3-TKD: *FLT3* tyrosine kinase domain mutation; CN-AML: cytogenetically normal AML

Figure 3: Multiple Cox regression models for overall survival. Multiple Cox regression models (for OS) were performed separately for patients in the AMLCG cohort (on the left) and AMLSG cohort (on the right). The models include all variables with p < 0.1 in the single Cox regression models of the primary cohort (AMLCG cohort). Significant p-values (<0.05) are marked with a star. CN-AML: cytogenetically normal AML; LDH: lactate dehydrogenase; pAML: primary AML; sAML: secondary AML; tAML: therapy-related AML; WBC: white blood cells

Figure 4: Differential isoform expression analysis in the AMLCG cohort. (A) Number of differentially expressed isoforms for each SF point mutation. (B) Isoforms reported as differentially expressed in the same direction among patients with different SF mutations vs. SF wildtype patients. HGNC symbols of the genes in which the common isoforms are located are shown. The corresponding Ensembl isoform identifiers are: 1. ENST00000340857, 2.

ENST00000481621, 3. ENST00000309668, 4. ENST00000258341, 5. ENST00000426532, 6. ENST00000562151, 7. ENST00000564133, 8. ENST00000368817, 9. ENST00000566524, 10. ENST00000530211. (C) Volcano plots showing the magnitude of differential isoform expression for *SRSF2*(P95H) and *SRSF2*(P95L). The x-axis corresponds to the log₂(fold change) of each isoform between mutated and wildtype samples, while the y-axis corresponds to –log10(FDR), where FDR represents the adjusted p-value for each isoform (False Discovery Rate).

Figure 5: Differential splice junction usage. (A) Scatterplot displaying the number of 606 607 samples as well as the total number of reads supporting each splice junction, separately for known and novel splice junctions in both RNA-Seq datasets. To preserve visibility 20000 608 609 random junctions are shown for each group. (B) Barchart showing the annotation status of 610 splice junctions reported as differentially used. Novel splice junctions where classified into 5 611 groups based on their annotation status as described previously[15] ("DA": annotated 612 junctions, "NDA": unknown combination of known donor and acceptor sites, "D": known donor, 613 but novel acceptor site, "A": novel donor, but known acceptor site, "N": previously unknown 614 donor and acceptor site). (C) Venn diagram showing the overlap of GO terms between 615 SRSF2(P95H) and SRSF2(P95L) mutants for the "biogical process" domain.

Figure 6: Splicing dysregulation in *SRSF2* mutants. (A) DSJU of all splice junctions inside *IDH3G* (ENSG00000067829) are shown for *SRSF2*(P95H) mutants compared to SF wildtype patients in the AMLCG and Beat AML cohort. To determine significance the log fold-change (logFC) of each splice junction (SJ) is compared to the logFC of all other junctions inside the same gene. The x-axis denotes individual splice junctions defined by their chromosomal coordinates (note the high number of splice sites shared by multiple splice junctions). (B)-(D) Nanopore sequencing results of one *SRSF2*(P95H) mutated sample and one SF wildtype

623 sample of the AMLCG cohort. The yellow boxes highlight examples of exon skipping (same 624 exons highlighted in (C) and (D). (B) FLAIR distribution of transcripts. Only one known isoform 625 is expressed in the samples. Additionally, two novel isoforms were detected which are virtually 626 mutually exclusive in the SRSF2(P95H) mutant and the SF wildtype sample. (C) Exon composition of known and novel isoforms detected (D). Sashimi plots showing the exon 627 628 sequence coverage as well as the splice junction usage of the SRSF2(P95H) mutated and SF 629 wildtype samples. The black arrow indicates the novel splice junction that is differentially used 630 in SRSF2(P95H) mutated samples compared to SF wildtype samples in both RNA-Seq 631 datasets shown in (A). (E) STRING plot depicting an interaction between SRSF2 and several 632 other splicing-related proteins including TRA2A. (F) Differential splice junction usage of all 633 splice junctions inside TRA2A (ENSG00000164548) are shown for SRSF2(P95H) and 634 SRSF2(P95L) mutants compared to SF wildtype patients. Annotation same as (A).





Figure 3

Valuation Hause Relia (c) (195) P Value Hause Relia (c) (195) P Value 731 AMUCOMB to AMUCOMA total - - CBI (261-105) + CBI (261-105) CBI (261-105) CBI (261-105) CBI	129	Overall Survival		AMLCG cohort		AMLSG cohort			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	730	Variables	Hazard Ratio (CI 95%)		P-Value	Hazard Ratio (CI 95%)		P-Value	
732 All GODS & ARCORD Fund $ -$	731	AMLHD98B vs AMLHD98A trial				0.80 (0.56 - 1.14)	⊢∎ 1	0.212	
733 All Cold Strand Cold Studie Date (54-22) Image: Cold Cold Cold Cold Cold Cold Cold Cold	732	AMLSG0704 vs AMLHD98A trial				0.40 (0.31 - 0.52)	H H H	<0.001*	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	733	AMLCG08 vs AMLCG99 trial	0.69 (0.54 - 0.87)		0.002 *	8			
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	734	sAML vs pAML	1.25 (0.96 - 1.63)	1	0.097	1.81 (1.16 - 2.83)		0.009*	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	735	tAML vs pAML	1.56 (1.08 - 2.25)		0.018*	1.66 (1.04 - 2.65)	· · · · · ·	0.034*	
	735	Female sex	0.97 (0.80 - 1.17)	H	0.738	1.01 (0.80 - 1.27)	H - -1	0.959	
	/30	Age (years), per 10 years	1.43 (1.32 - 1.55)		<0.001*	1.68 (1.46 - 1.95)		<0.001*	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	131	WBC (10^9/L), per 50 units	1.16 (1.11 - 1.22)	•	<0.001*	1.35 (1.21 - 1.51)	-	<0.001*	
739 AXX.1 060071-120 0730 155070-180 077 740 50008 101077-120 0400 <t< td=""><td>738</td><td>LDH (U/L), per 500 units</td><td>1.07 (1.04 - 1.10)</td><td>•</td><td><0.001*</td><td>1.13 (1.03 - 1.25)</td><td>-</td><td>0.011*</td></t<>	738	LDH (U/L), per 500 units	1.07 (1.04 - 1.10)	•	<0.001*	1.13 (1.03 - 1.25)	-	0.011*	
740 ECR 10 (27-120) Image: constraint of the constraint of th	739	ASXL1	0.95 (0.71 - 1.27)	H	0.723	1.15 (0.70 - 1.89)	⊢	0.577	
741 CEBPA (kulaship) 0.44 (0.27-0.88) 0.45 (0.21-0.80) 0.45 (0.21-	740	BCOR	1.01 (0.73 - 1.39)	⊢ ∎i	0.953	0.86 (0.44 - 1.66)	·	0.647	
MAX 191 (10) - 369 0 - 0159 <	741	CEBPA (biallelic)	0.44 (0.22 - 0.88)	HH	0.019*	0.45 (0.21 - 0.98)	H	0.045*	
NT 0.773 NT $0.793 - 1.77$ 0.79 $0.89(0.27 - 1.57)$ 0.755 $0.004 + 102(0.62 - 197)$ 0.755 744 NPM1 $0.80(0.57 - 0.85)$ $0.004 + 102(0.62 - 197)$ $0.004 + 102(0.62 - 197)$ $0.004 + 102(0.62 - 197)$ $0.004 + 102(0.62 - 197)$ $0.004 + 102(0.62 - 197)$ $0.004 + 102(0.62 - 197)$ $0.004 + 102(0.62 - 197)$ $0.004 + 102(0.62 - 197)$ $0.004 + 102(0.62 - 197)$ $0.004 + 102(0.62 - 130)$ $0.004 + 102(0.62 - 130)$ $0.004 + 102(0.62 - 130)$ $0.004 + 102(0.62 - 130)$ $0.004 + 102(0.62 - 127)$ $0.004 + 102(0.62 - 127)$ $0.004 + 102(0.62 - 127)$ $0.004 + 102(0.62 - 127)$ $0.004 + 102(0.62 - 127)$ $0.004 + 102(0.62 - 128)$ $0.004 $	742	JAK2	1.91 (1.00 - 3.68)		0.052	0.69 (0.29 - 1.68)	II	0.418	
14-3 KRAS 151 (150-2.2) 0.00+* 102 (02.019) 0.755 744 NPM1 0.68 (051-0.8) + 0.00+* 0.76 (0.50-100) + 0.005 745 NRAS 0.98 (0.00-1.13) + 0.00+* 0.76 (0.50-100) + 0.005 746 PTPN11 0.89 (0.00-1.13) + 0.045 0.04 (0.00-1.30) + 0.056 747 RUXK1 1.40 (107-1.84) + 0.055 1.11 (0.77-1.59) + 0.805 749 SISS2 (PSB4) 0.38 (0.25-1.70) + 0.057 1.36 (0.72-2.30) + 0.077 750 SISS2 (PSB4) 0.10 (0.31-13) + 0.058 1.36 (0.72-2.40) + 0.953 751 SISS2 (PSB4) 1.30 (0.32-1.33) + 0.046 0.80 (0.2-1.50) + 0.977 752 SIGG2 1.00 (0.97-1.47) + 0.046 0.80 (0.2-1.50) + 0.977 754 TPS3 1.20 (0.01-10) + 0.020 0.070-1.30) + 0.977	7/2	КІТ	0.67 (0.39 - 1.17)	H	0.159	0.86 (0.47 - 1.57)	P	0.624	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	743	KRAS	1.61 (1.16 - 2.24)	⊢∎→	0.004*	1.09 (0.62 - 1.91)	·1	0.755	
745 NRAS 0.89 (0.71-13) Image: formed base (0.64-120) Image: for	744	NPM1	0.66 (0.51 - 0.85)	H H H	0.001*	0.76 (0.56 - 1.05)	■ (0.096	
746 PTPH1 0.89 (0.61-120) Image: first state stat	745	NRAS	0.89 (0.71 - 1.13)		0.334	0.88 (0.64 - 1.20)	H - -1	0.413	
747 RUX1 1.0(157-150) 0.015 1.11(0.77-150) 0.882 748 sF381 (ofbor) 128 (0.76-2.11) 0.051 0.084 (0.17-2.30) 0.070 749 ssr32 (ofbor) 128 (0.76-2.11) 0.070 0.069 1.08 (0.52-2.17) 0.070 750 ssr32 (ofbor) 128 (0.76-2.11) 0.010 0.021 1.06 (0.52-2.17) 0.070 751 ssr32 (ofbor) 102 (0.64-1.62) 0.045 0.806 1.28 (0.57-2.68) 0.077 752 stazz 108 (0.76-1.47) 0.045 0.806 (0.52-1.53) 0.077 753 TET2 0.87 (0.86-1.16) 0.034 0.306 (0.70-1.39) 0.097 754 TP33 120 (0.81-1.86) 0.034 1.30 (0.83-3.10) 0.016 755 U2AF1 (0.847) 1.10 (0.71-0.29) 0.034 1.03 (0.60-3.10) 0.017 755 U2AF1 (0.847) 1.00 (0.80-1.08) 0.034 1.00 (0.80-3.10) 0.017 756 zessez 1.38 (0.60-2.01) 0.016 0.016 0.016 0.016 0.016 0.016 0.017 0.017 756 </td <td>746</td> <td>PTPN11</td> <td>0.89 (0.66 - 1.20)</td> <td>⊢∎−1</td> <td>0.445</td> <td>0.90 (0.59 - 1.36)</td> <td>1</td> <td>0.608</td>	746	PTPN11	0.89 (0.66 - 1.20)	⊢ ∎−1	0.445	0.90 (0.59 - 1.36)	 1	0.608	
748 8780 (pToPe) 0.08 (0.5 - 1.7) Image: Comparison of the co	747	RUNX1	1.40 (1.07 - 1.84)	F	0.015*	1.11 (0.77 - 1.59)		0.582	
749 SF381 (other) 1.28 (0.76 - 2.11) 0.370 1.08 (0.22 - 2.17) 0.870 750 SRS52 (PSH) 0.91 (0.83 - 1.33) 0.639 1.38 (0.77 - 2.41) 0.284 751 SRS52 (PSH) 1.33 (0.83 - 2.13) 0.456 0.868 (0.52 - 1.53) 0.883 751 SRS52 (Other) 1.02 (0.64 - 1.62) 0.845 0.868 (0.52 - 1.53) 0.883 752 STA02 1.08 (0.76 - 1.47) 0.856 1.38 (0.87 - 2.06) 0.877 753 TET2 0.87 (0.68 - 1.10)	748	SF3B1 (K700E)	0.98 (0.55 - 1.76)	— •	0.951	0.64 (0.17 - 2.38)		0.506	
SR52 (9564) 0.51 (0.63 - 1.33) 0.639 1.36 (0.77 - 241) 0.224 750 sr852 (9564) 1.33 (0.83 - 213) 0.945 0.890 1.36 (0.54 - 289) 0.659 751 sr852 (0464) 1.02 (0.64 - 1.82) 0.945 0.890 (0.52 - 1.53) 0.677 752 sr3622 1.06 (0.79 - 1.47) 0.945 0.890 (0.52 - 1.53) 0.677 753 TET2 0.67 (0.86 - 1.00) 0.200 0.600 (0.57 - 1.39) 0.176 754 TP33 1.29 (0.81 - 1.85) 0.315 1.58 (1.12 - 3.8) 0.977 756 ZESR2 1.38 (0.85 - 2.91) 0.034+ 1.39 (0.85 - 3.10) 0.416 757 CN-AML 0.84 (0.66 - 1.05) 0.726 0.74 (0.26 - 2.13) 0.977 757 CN-AML 0.84 (0.66 - 1.05) 0.043+ 1.83 (0.05 - 2.60) 0.075 758 Complex AML 1.73 (1.02 - 2.80) 0.043+ 1.63 (1.00 - 2.60) 0.051 760 inv(169) (16(3) 1.44 (0.72 - 1.80) 0.001+ 0.31 (0.14 - 0.60) 0.043+ 761 del(69/ del(6q) 1.44 (0.72 - 1.80)	749	SF3B1 (other)	1.26 (0.76 - 2.11)		0.370	1.06 (0.52 - 2.17)	⊢	0.870	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	750	SRSF2 (P95H)	0.91 (0.63 - 1.33)		0.639	1.36 (0.77 - 2.41)		0.294	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	751	SRSF2 (P95L)	1.33 (0.83 - 2.13)	H•	0.232	1.26 (0.54 - 2.89)		0.593	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	751	SRSF2 (other)	1.02 (0.64 - 1.62)		0.945	0.89 (0.52 - 1.53)		0.677	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	152	STAG2	1.08 (0.79 - 1.47)		0.636	1.35 (0.87 - 2.08)		0.176	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	753	TET2	0.87 (0.68 - 1.10)	H -	0.230	0.99 (0.70 - 1.39)		0.957	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	754	1953	1.25 (0.81 - 1.95)		0.315	1.95 (1.12 - 3.39)		0.018*	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	755	U2AF1 (S34F)	1.90 (1.05 - 3.45)		0.034*	1.39 (0.63 - 3.10)		0.416	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	756	JOSEP (other)	1.28 (0.65 - 2.05)		0.726	0.74 (0.26 - 2.13)		0.577	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	757	CN AMI	0.84 (0.65 - 1.08)		0.404	2.33 (0.62 - 0.03)		0.506	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	758		1 73 (1 02 - 2 93)		0.043*	1.63 (1.00 - 2.68)		0.000	
759 Integrate(s) Lot (117 + 165) 760 inv(16)/(16:16) 0.32 (0.17 - 0.62) Image: constraint of the second secon	750	inv(3)/ t(3:3)	2 35 (1 11 - 4 99)		0.026*	2.07 (0.66 - 6.53)		0.214	
760 Intervention Intervention 761 del(5)/ del(5q) 1.14 (0.72 - 1.80) -7 1.11 (0.73 - 1.68) 762 -7 del(17)/ abn(17p) 1.00 (0.60 - 1.64) 0.10 0.10 <	759	inv(16)/ t(16:16)	0.32 (0.17 - 0.62)		0.001*	0.31 (0.14 - 0.68)		0.004*	
761 -7 1.11 (0.73 - 1.68) 762 -7 1.11 (0.73 - 1.68) del(17)/ abn(17p) 1.00 (0.60 - 1.64) 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.11 0.11 0.12 </td <td>/00</td> <td>del(5)/ del(5a)</td> <td>1.14 (0.72 - 1.80)</td> <td></td> <td>0.567</td> <td>1.26 (0.70 - 2.29)</td> <td></td> <td>0.445</td>	/00	del(5)/ del(5a)	1.14 (0.72 - 1.80)		0.567	1.26 (0.70 - 2.29)		0.445	
762 del(17)/ abn(17p) 1.00 (0.60 - 1.64) 0.986 0.79 (0.44 - 1.44) 0.448 763 0.10 0.10 0.10 0.10 0.10 0.10 0.448 764 Hazard Ratio Hazard Ratio Hazard Ratio Hazard Ratio 765 766 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.10<	/61	-7	1.11 (0.73 - 1.68)		0.620	1.77 (1.01 - 3.10)		0.048*	
763 764 765 766	762	del(17)/ abn(17p)	1.00 (0.60 - 1.64)	·	0.986	0.79 (0.44 - 1.44)		0.448	
764 Hazard Ratio Hazard Ratio 765 766	763			0.10 0.18 0.35 0.70 1.4 2.8 5.	0		0.10 0.18 0.35 0.70 1.4 2.8 5	Т 5.0	
765 766	764			Hazard Ratio			Hazard Ratio		
766	765								
	766								





